Sandoz Follows US Denosumab Filing With European Acceptance
Dual Filings With EMA For Prolia/Xgeva Biosimilars Confirmed By Novartis Unit
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
You may also be interested in...
Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global
Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.
Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.